Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$502.34M+80.6%$278.1M+236%$82.79M+130%-$279.86M-21.4%-$230.47M+17.1%
$54.81M-1.5%$55.66M-1.2%$56.32M-0.3%$56.5M-1.8%$57.56M+1.6%
$361.68M+3.9%$348.24M-5.4%$368.25M+20.4%$305.84M+7.9%$283.45M+4.2%
$714.9M+36.4%$524.08M+97.1%$265.86M+1,811%-$15.54M+67.0%-$47.11M-467%
$71.56M+21.9%$58.7M+31.9%$44.5M+21.8%$36.55M+20.7%$30.27M-11.7%
$334.18M-29.4%$473.5M+12.6%$420.59M+480%-$110.77M
-$319.51M-238%$231.59M-25.6%$311.33M+5.8%
$690.17M0.0%$690.16M
$643.34M+38.2%$465.38M+110%$221.36M+525%-$52.09M+32.7%-$77.38M-81.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Alnylam Pharmaceuticals generate?
Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
What is Alnylam Pharmaceuticals's free cash flow?
After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
Where does Alnylam Pharmaceuticals's cash flow data come from?
Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.